Company profile
InMed Pharmaceuticals Inc.
NASDAQ: INM · Healthcare · Biotechnology
Canadian filerHQ Vancouver, BCCIK 0001728328Reports USD
#711 of 1,417 Healthcare companies by revenue52nd-percentile growth
EA Score
45DFH 41DQ 45GM 57SS 42
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$4.0M
Rev growth YoY (TTM)
-18.3%
Net income (FY)
-$8.2M
Employees
13
as of 2026-08-24
Market cap
$2.6M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.9M$4.9M2025
Net income-$8.2M-$8.2M2025
Operating income-$7.9M-$7.9M2023
Total assets$15.6M$15.6M2025
Liabilities$2.1M$2.1M2025
Equity$13.4M$13.4M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is InMed Pharmaceuticals Inc.’s revenue?
InMed Pharmaceuticals Inc. booked $4.9M in FY2025 revenue, growing 7.5% year over year — about the middle of the pack among Healthcare companies we track, at a -165.1% net margin.
Peers · Healthcare
Ensysce Biosciences, Inc.31DBanyan Corp.——Procyon Corporation——Picard Medical, Inc.25DLucid Diagnostics Inc.35DPrime Medicine, Inc.37DKey facts
CEOEric A. Adams Chem.
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, BC
ExchangeNASDAQ: INM
Employees13
IPO date2014-05-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.